ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för linagliptin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

74 träffar

Bibliografisk träff 2010-12-01

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle HJ, Dugi KA.

Diabet Med · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1464-5491.2010.03131.x

Bibliografisk träff 2010-11-12

Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.

Graefe-Mody U, Rose P, Ring A, Ring A, Zander K, Iovino M, Woerle HJ.

Drug Metab Pharmacokinet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.2133/dmpk.dmpk-10-rg-091

Bibliografisk träff 2010-10-01

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.

Graefe-Mody EU, Jungnik A, Ring A, Woerle HJ, Dugi KA.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.5414/cpp48652

Bibliografisk träff 2010-06-10

The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.

Greischel A, Binder R, Baierl J.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.110.034199

Bibliografisk träff 2010-06-01

Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.

Graefe-Mody U, Huettner S, Stähle H, Ring A, Dugi KA.

Int J Clin Pharmacol Ther · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.5414/cpp48367

Bibliografisk träff 2010-06-01

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.

Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2010.06.004

Bibliografisk träff 2010-02-16

Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.

Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A.

J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1177/0091270009356444

Bibliografisk träff 2010-01-19

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.

Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K.

Drug Metab Dispos · randomized controlled trial; journal article · DOI 10.1124/dmd.109.031476

Bibliografisk träff 2010-01-01

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.

Deacon CF, Holst JJ.

Expert Opin Investig Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.1517/13543780903463862

Bibliografisk träff 2009-11-01

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.

Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H.

Biopharm Drug Dispos · journal article · DOI 10.1002/bdd.676

Bibliografisk träff 2009-10-01

Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Tiwari A.

Curr Opin Investig Drugs · review; journal article

Bibliografisk träff 2009-09-05

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.

Horie Y, Hayashi N, Dugi K, Takeuchi M.

Trials · clinical trial, phase iii; clinical trial, phase ii; comparative study; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1186/1745-6215-10-82

Bibliografisk träff 2009-08-01

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

Graefe-Mody EU, Padula S, Ring A, Ring A, Withopf B, Dugi KA.

Curr Med Res Opin · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1185/03007990903094361

Bibliografisk träff 2009-05-19

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA.

Diabetes Obes Metab · multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2009.01046.x